Fernando Roncolato

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes

Ashwin Unnikrishnan, Elli Papaemmanuil, Dominik Beck et al. · Cell Reports · 2017 · 123 citations · Full text

Non-responder Hpc Quiescence, Mixed-phenotype Acute Leukemia, Genetics +19

A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)

Philip Choi, Fernando Roncolato, Xavier C. Badoux et al. · Blood · 2015 · 72 citations · Full text

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Amer M. Zeidan, Daniel A. Pollyea, Jacqueline S. Garcia et al. · Blood · 2019 · 71 citations

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

Amer M. Zeidan, Uma Borate, Daniel A. Pollyea et al. · American Journal of Hematology · 2022 · 70 citations · Full text

Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

Yuqin Song, Luis Malpica, Qingqing Cai et al. · The Lancet Oncology · 2023 · 43 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8